Moderna Doses First Patient in mRNA-4200 Cancer Trial
CAMBRIDGE, Mass., July 16, 2026 Moderna, Inc. has announced the first participant has been dosed in its Phase 1...
Immunotherapy
Advertisement
Intensity Therapeutics Restarts Phase 2 TNBC Trial
SHELTON, Conn., July 15, 2026 Intensity Therapeutics, Inc. has restarted patient treatment in its Phase 2 INVINCIBLE-4 clinical trial...
Zelluna Doses First Patient With TCR-NK Therapy
OSLO, Norway, July 13, 2026 Zelluna announced that the first patient has been dosed in the ZIMA-101 Phase 1...
Antengene and UCB Advance ATG-201 Partnership with $60M Payment
SHANGHAI and HONG KONG, China, July 13, 2026 Antengene has announced the receipt of a USD 60 million upfront...
Immutep Reports Positive INSIGHT-003 Survival Data
SYDNEY, Australia, July 13, 2026 Immutep announced positive mature overall survival data from its investigator-initiated Phase 1 INSIGHT-003 trial...
Advertisements
IN8bio Publishes Positive Phase 1 GBM Data
NEW YORK, July 9, 2026 IN8bio announced the publication of peer-reviewed Phase 1 clinical trial results for its investigational...
LEO Pharma Reports Positive Phase 2 Tralokinumab Results
BALLERUP, Denmark, July 9, 2026 LEO Pharma A/S has announced positive results from the Phase 2 TRAPEDS-1 clinical trial...
Merck Announces Expanded FDA Approval for Keytruda in MIBC
SILVER SPRING, Maryland, July 10, 2026 Merck has received U.S. Food and Drug Administration (FDA) approval for Keytruda® (pembrolizumab)...
MAIA Biotechnology Reports Positive Phase 2 THIO-101 Data in Third-Line NSCLC
CHICAGO, July 8, 2026 MAIA Biotechnology announced encouraging interim efficacy results from Part C of its Phase 2 THIO-101...
Leads Biolabs Secures Priority Review for Opamtistomig
NANJING, China | July 10, 2026 Nanjing Leads Biolabs Co., Ltd. has announced that the Center for Drug Evaluation...
Advertisement
